Table II.
Univariate and multivariate analysis of prognostic factors of OS in patients with castration-resistant prostate cancer who were administered DTX.
| Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
| Variables | HR | 95% CI | P-value | HR | 95% CI | P-value |
| Age, years | ||||||
| <70 | 1 | 0.33 | ||||
| ≥70 | 1.6 | 0.6–3.8 | ||||
| PSA at diagnosis, ng/ml | ||||||
| <70 | 1 | 0.49 | ||||
| ≥70 | 0.7 | 0.3–1.8 | ||||
| Total Gleason Score | ||||||
| Up to 4+4 | 1 | 0.075 | ||||
| 4+5, 5+4, 5+5 | 2.7 | 0.9–8.2 | ||||
| Clinical T stage | ||||||
| <3 | 1 | 0.91 | ||||
| ≥3 | 1.1 | 0.3–3.8 | ||||
| Clinical N stage | ||||||
| <1 | 1 | 0.14 | ||||
| ≥1 | 1.9 | 0.8–4.9 | ||||
| Clinical M stage | ||||||
| 0 | 1 | 0.83 | ||||
| 1 | 0.9 | 0.4–2.3 | ||||
| RP as Primary therapy | ||||||
| No | 1 | 0.4 | ||||
| Yes | 0.59 | 0.2–2.1 | ||||
| Period from ADT to DTX, months | ||||||
| <25 | 1 | 0.17 | ||||
| ≥25 | 0.5 | 0.2–1.3 | ||||
| PSA nadir of ADT, ng/ml | ||||||
| <2 | 1 | 0.69 | ||||
| ≥2 | 1.2 | 0.5–3.0 | ||||
| Time from PSA nadir of ADT to DTX, months | ||||||
| <20 | 1 | 0.68 | ||||
| ≥20 | 0.83 | 0.3–2.1 | ||||
| PSA at starting of DTX | ||||||
| <50 | 1 | 0.77 | ||||
| ≥50 | 0.9 | 0.4–2.1 | ||||
| KLA | ||||||
| Low | 1 | 0.43 | ||||
| High | 0.7 | 0.3–1.7 | ||||
| KLB | ||||||
| Low | 1 | 0.032 | 1 | 0.27 | ||
| High | 3.3 | 1.1–10.1 | 2 | 0.6–7.3 | ||
| KLG | ||||||
| Low | 1 | 0.029 | 1 | 0.012 | ||
| High | 3.9 | 1.1–13.5 | 3.9 | 1.1–13.4 | ||
KLB and KLG were prognostic factors of OS in univariate analysis. In multivariate analysis, KLG was an independent prognostic factor. OS, overall survival; PSA, prostate specific antigen; RP, radical prostatectomy; ADT, androgen-deprivation therapy; DTX, docetaxel; KLA, α-Klotho; KLB, β-Klotho; KLG, γ-Klotho; HR, hazard ratio; CI, confidence interval.